NCT01732627View on ClinicalTrials.gov

Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older

PHASE2CompletedINTERVENTIONAL

Enrollment

301

Participants

Timeline

Start Date

November 12, 2012

Primary Completion Date

January 17, 2013

Study Completion Date

January 17, 2013

Conditions

MeningitisMeningococcal MeningitisMeningococcal InfectionsInvasive Meningococcal Disease

Interventions

BIOLOGICAL

Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine

0.5 milliliter (mL), Intramuscular (IM)

BIOLOGICAL

Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W 135 Combined

0.5 mL, Subcutaneous (SC)

Trial Locations (12)

22911

Charlottesville

29621

Anderson

43212

Columbus

55435

Edina

63141

St Louis

80239

Denver

84088

West Jordan

84123

Murray

84124

Salt Lake City

85224

Chandler

85251

Scottsdale

06460

Milford

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT01732627 - Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older | Biotech Hunter | Biotech Hunter